Fig. 1
a Lung Function and Estradiol Change Over Time. Relative stability in ppFEV1 (left sided Y axis; solid circles) until the introduction and escalation of exogenous estrogen therapy with rising serum estradiol levels (right sided Y axis; open squares), in spite of ongoing itraconazole, pulse steroid and benralizumab treatment (period of treatment denoted by the horizontal bars). Arrows denote start and dose adjustment dates of cyproterene and estrogen. * denotes pulmonary exacerbations requiring oral antibiotic treatment. # denotes pulmonary exacerbations requiring intravenous antibiotic treatment. Percent predicted forced expiratory volume in 1 s (ppFEV1) was determined in accordance with Global Lung Function Initiative 2012 spirometry equations. b Blood Eosinophil and IgE Change Over Time. Sustained rise in IgE levels (left sided Y axis; solid squares) corresponding to estrogen therapy in spite of ongoing itraconazole, pulse steroid and benralizumab treatment (period of treatment denoted by the horizontal bars). Serum eosinophil levels (right sided Y axis; open triangles) drop in response to benralizumab therapy. Arrows denote start and dose adjustment dates of cyproterene and estrogen. * denotes pulmonary exacerbations requiring oral antibiotic treatment. # denotes pulmonary exacerbations requiring intravenous antibiotic treatment